Steering Committee

Steven Gilmore, PharmD, BCOP is a Senior Manager of clinical content at McKesson Specialty Health and provides support to the US Oncology Network through management of the EHR, Value Pathways, Patient Education, and Regimen Profiler. Steven's background is in clinical oncology practice with experience in acute and ambulatory practices managing education and monitoring for chemotherapy and oral oncolytics.

Jill Miller, PA-C, is Manager of the Leukemia Outpatient Advanced Practice Providers at MD Anderson Cancer Center. She has led the outpatient APP team since 2015 and first joined the Leukemia Department in 2009. She completed the Postgraduate Physician Assistant Fellowship in Oncology at MD Anderson in 2008, following her graduation from Baylor College of Medicine’s PA Program in 2007. She remains involved in the Fellowship as an advisor and preceptor, along with precepting PA students on a regular basis. She also continues to serve Baylor College of Medicine as President of the Alumni Executive Committee and instructor of the Hematology Critical Thinking Sessions for the PA program.

Karley Trautman, DNP, ANP-BC, AGACNP-BC is an experienced nurse practitioner with over 13 years of experience working with oncology patients in both inpatient and outpatient settings. The first part of her career was focused on blood cancers in the academic hospital setting of University of Colorado Hospital and more recently in a community focused practice seeing both solid tumor and malignant hematology patients at Highlands Ranch Hospital. Karley is a strong advocate for advanced practice as a profession and enjoys engaging in local and national events to elevate the profession and improve patient care.

Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, is the clinical oncology pharmacy manager and a practicing hematology clinical pharmacist at Atrium Health Levine Cancer in Charlotte, North Carolina. Dr. Moore’s clinical interests include lymphoma, multiple myeloma, chronic leukemias, immune thrombocytopenic purpura, and thrombotic microangiopathies as well as pharmacovigilance, professional writing, and research.

Dr. Moore is a member of the American College of Clinical Pharmacy (ACCP), the American Society of Health-System Pharmacists (ASHP), the Hematology/Oncology Pharmacy Association, and the Advanced Practitioner Society for Hematology and Oncology. He is also a graduate of the ASHP Foundation Pharmacy Leadership Academy and was named a 40 Under 40 in Cancer Award recipient by the National Community Oncology Dispensing Association and Swim Across America. He is also recognized as a fellow of ACCP.

Dr. Moore earned his pharmacy degree from Massachusetts College of Pharmacy and Health Sciences. He completed his residency at Steward St. Elizabeth’s Medical Center in Boston, Massachusetts.

Dr. Amy DeZern is a hematologist and Professor of Oncology and Medicine at the Johns Hopkins University School of Medicine. Dr. DeZern’s primary clinical and research interests are focused on bone marrow failure disorders. She has expertise in the diagnosis and treatment of aplastic anemia (AA), myelodysplastic syndromes (MDS), clonal hematopoiesis (CH), and paroxysmal nocturnal hemoglobinuria (PNH) as well as acute leukemias. She is an active clinician-scientist who specializes in clinical trials of diagnostics and therapeutics for these disorders. She has been the principal investigator for over 40 single-center and multicenter clinical trials in MDS and AA.  These investigator-led initiatives focus on transplant therapies in AA (including the upcoming BMT CTN upfront trial for SAA) and novel therapeutics (Phase 1-3 trials) in MDS. Additionally, Dr. DeZern is the deputy co-chair of The National MDS Study.

David Sallman, MD is an associate member in the Department of Malignant Hematology at Moffitt Cancer Center and assistant professor in the Department of Oncologic Sciences at the University of South Florida, both in Tampa, Florida. He is also the myeloid section head of the Malignant Hematology Department. Dr Sallman’s clinical interests are myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and myeloproliferative neoplasms. His research interests focus on the development of novel targeted therapeutic strategies (phase 1 and 2 clinical trials) for patients with MDS and AML, based on the underlying mutational drivers of each disease. Specifically, he studies the genetic drivers of myeloid diseases to improve prognostication for patients and to allow for more personalized treatment and has published significantly on this topic.

Dr. Sallman is the principal investigator for multiple ongoing studies focused on higher-risk MDS, including his recent work on TP53-mutant MDS, and he has been the lead principal investigator for phase 1-3 trials TP53-mutant MDS and AML patients. Additionally, he serves as lead PI for multiple cellular therapy trials including CAR-T and TCR therapies. Dr. Sallman has authored or coauthored numerous articles, books, book chapters, and abstracts and serves as reviewer for multiple journals. He received the Young Investigator Grant from the MDS Foundation in 2017 and the Dresner Foundation Career Development award in 2018.

Dr. Sallman earned his medical degree from the University of South Florida College of Medicine and completed an internal medicine residency at Massachusetts General Hospital before completing a hematology/oncology fellowship at Moffitt Cancer Center. He is board certified in medical oncology, hematology, and internal medicine.

Robin B. Atkins, RN, is a registered nurse with specialty certification in oncology nursing (OCN®). She is currently working as a symptom management oncology triage nurse at Virginia Oncology Associates. In addition to critically assessing patient symptoms by phone, she educates patients and families on how to recognize and minimize toxicities, maintain and improve nutritional sustenance and general health, cope with uncertainty, and navigate unexpected experiences (e.g., the COVID-19 pandemic). Helping patients understand complex oncology concepts and multimodality treatment options while meeting meaningful life goals along the cancer care trajectory and teaching them how to advocate for themselves or loved ones, are valued aspects of the holistic triage services Mrs. Atkins provides. Her top priorities include dedicated follow-up on response to symptom management strategies to ensure successful treatment outcomes for patients and reduction of unnecessary emergency department visits and hospitalizations by patients.

Robin Atkins is a veteran outpatient medical hematology-oncology nurse of 35 years, certified in the specialty through the Oncology Nursing Society (ONS). She graduated from Riverside School of Professional Nursing with honors in 1985. Her clinical interests include patient and staff education, professional development, and various volunteer roles within the ONS including being a member of the Oncology Certified Nurse Test Development Committee and being a peer editor/reviewer for the ONS Clinical Journal of Oncology Nursing (CJON) and a chapter in the upcoming 4th edition of the ONS Safe Handling of Hazardous Drugs. Her additional volunteer roles within ACCC are priorities for her as well including authoring the ACCCBuzz Blog post Notes on Nursing, serving on various steering committees including ACCC Communication and ACCC Small Cell Lung Cancer committees. Lastly, she served as a career mentor twice with the American Nurses Association Mentorship program since 2016. She enjoys process improvement projects, coordinating care, and patient education. She lives in Gloucester County, VA with her husband of 35 years and two cats Gracie and Annie. They spend a lot of time off the grid camping and canoeing in the mountains of Virginia. Robin enjoys singing, binge watching British detective series, and cooking for her family.

.